Vertex Pharmaceuticals Inc (NAS:VRTX)
$ 422.78 3.79 (0.9%) Market Cap: 109.10 Bil Enterprise Value: 99.65 Bil PE Ratio: 27.44 PB Ratio: 5.89 GF Score: 94/100

Q4 2020 Vertex Pharmaceuticals Inc Earnings Call Transcript

Feb 01, 2021 / 09:30PM GMT
Release Date Price: $231.77 (+1.17%)
Michael Partridge
Vertex Pharmaceuticals Incorporated - SVP of IR

Making prepared remarks on the call tonight, we have Dr. Reshma Kewalramani, Vertex's CEO and President; Stuart Arbuckle, Chief Commercial Officer; and Charlie Wagner, Chief Financial Officer. Dr. David Altshuler, Chief Scientific Officer; and Dr. Bastiano Sanna, Chief of Cell and Genetic Therapies, will join the Q&A portion of the call following the prepared remarks.

We recommend that you access the webcast slides on our website as you listen to this call. This conference call is being recorded, and a replay will be available on our website.

We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and our filings with the Securities and Exchange Commission. These statements, including, without limitation, those regarding Vertex's marketed CF medicines, our pipeline and Vertex's future financial performance, are based on management's current assumptions. Actual outcomes and events could differ materially. I would also note that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot